
Harpoon Therapeutics
A clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.
Market cap
$492m
Enterprise value
$475m
Share price
$23.01 HARP
Authorizing premium user...